Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

4.580 -0.050 (-1.08%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vanda Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst ↗

November 01, 2024

HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product portfolio, and growth in neurology.

Via Benzinga

Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today ↗

September 19, 2024

A regulator's decision drained the market's enthusiasm for the company.

Via The Motley Fool

FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies ↗

September 19, 2024

The FDA rejected Vanda Pharmaceuticals' new drug application for tradipitant to treat gastroparesis, citing the need for more studies despite delays in its review process. Vanda argues the drug meets...

Via Benzinga

Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment

August 06, 2024

New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves...

Via PressReach

Why Vanda Pharmaceuticals Stock Is Skyrocketing Today ↗

April 17, 2024

Future Pak wants Vanda, but Vanda doesn't want Future Pak.

Via The Motley Fool

Earnings Scheduled For February 13, 2025 ↗

February 13, 2025

Via Benzinga

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

February 03, 2025

From AnaptysBio, Inc.

Via GlobeNewswire

A Glimpse Into The Expert Outlook On Vanda Pharma Through 4 Analysts ↗

January 28, 2025

Via Benzinga

FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate ↗

January 16, 2025

FDA denies Vanda's Tradipitant application for gastroparesis, urging new trials for efficacy and safety. Vanda disputes the agency's review process.

Via Benzinga

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

December 16, 2024

From Glancy Prongay & Murray LLP

Via Business Wire

What's Going On With Vanda Pharmaceuticals Shares Today? ↗

June 27, 2024

Vanda Pharmaceuticals shares decline as Future Pak withdraws acquisition offer following Vanda's rejection and lack of response.

Via Benzinga

Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 20, 2024

Via Benzinga

Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

June 20, 2024

Via Benzinga

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 20, 2024

Via Benzinga

Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday ↗

June 13, 2024

Via Benzinga

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

June 10, 2024

From Glancy Prongay & Murray LLP

Via Business Wire

S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat ↗

June 06, 2024

Via Benzinga

Topics Stocks

Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 06, 2024

Via Benzinga

Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings ↗

June 06, 2024

Via Benzinga

Vanda Pharmaceuticals Receives Another Takeover Proposal, Considers $466M Deal ↗

June 06, 2024

Cycle Pharmaceuticals wants to acquire Vanda Pharmaceuticals for $8 per share, or $466 million. Cycle focuses on rare neurological conditions.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

June 06, 2024

Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning!

Via InvestorPlace

Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

May 09, 2024

Via Benzinga

VNDA Stock Earnings: Vanda Pharma Misses EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

VNDA stock results show that Vanda Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals

April 25, 2024

From Shareholder Capital LLC

Via GlobeNewswire

US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz ↗

April 22, 2024

"Supreme Court denies review of Vanda Pharmaceuticals' patent revival attempt for Hetlioz sleep-disorder medication. Legal battle details, implications, and market impact."

Via Benzinga

Topics Intellectual Property

Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views ↗

April 17, 2024

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21....

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 17, 2024

Via Benzinga

Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share ↗

April 17, 2024

Vanda Pharmaceuticals rebuffs unsolicited proposals from Future Pak LLC, citing undervaluation. Offers up to $7.75 per share. Board asserts resilient business with FDA-approved products. Future Pak...

Via Benzinga

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 17, 2024

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

Via Benzinga

Why Is Trio Petroleum (TPET) Stock Down 22% Today? ↗

April 17, 2024

Trio Petroleum stock is falling on Wednesday as TPET investors learn of a securities purchase agreement and Senior Secured Note.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.